JP7589045B2 - リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法 - Google Patents

リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法 Download PDF

Info

Publication number
JP7589045B2
JP7589045B2 JP2020551266A JP2020551266A JP7589045B2 JP 7589045 B2 JP7589045 B2 JP 7589045B2 JP 2020551266 A JP2020551266 A JP 2020551266A JP 2020551266 A JP2020551266 A JP 2020551266A JP 7589045 B2 JP7589045 B2 JP 7589045B2
Authority
JP
Japan
Prior art keywords
ige
dose
antibody
antigen
ligelizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523881A (ja
JP2021523881A5 (https=
JPWO2019186369A5 (https=
Inventor
セヴリン，トーマス
ロウ，フィリップ
マーティン ジャノチャ，レイノルド
ケーネ－ヴォス，ステファン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021523881A publication Critical patent/JP2021523881A/ja
Publication of JP2021523881A5 publication Critical patent/JP2021523881A5/ja
Publication of JPWO2019186369A5 publication Critical patent/JPWO2019186369A5/ja
Application granted granted Critical
Publication of JP7589045B2 publication Critical patent/JP7589045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2020551266A 2018-03-26 2019-03-25 リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法 Active JP7589045B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647928P 2018-03-26 2018-03-26
US62/647,928 2018-03-26
US201962811800P 2019-02-28 2019-02-28
US62/811,800 2019-02-28
PCT/IB2019/052408 WO2019186369A1 (en) 2018-03-26 2019-03-25 Methods of treating chronic spontaneous urticaria using ligelizumab

Publications (4)

Publication Number Publication Date
JP2021523881A JP2021523881A (ja) 2021-09-09
JP2021523881A5 JP2021523881A5 (https=) 2022-03-31
JPWO2019186369A5 JPWO2019186369A5 (https=) 2022-03-31
JP7589045B2 true JP7589045B2 (ja) 2024-11-25

Family

ID=66476672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551266A Active JP7589045B2 (ja) 2018-03-26 2019-03-25 リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法

Country Status (9)

Country Link
US (2) US20210115155A1 (https=)
EP (1) EP3773904A1 (https=)
JP (1) JP7589045B2 (https=)
KR (1) KR20200135826A (https=)
CN (1) CN112203724A (https=)
AU (1) AU2019244666A1 (https=)
CA (1) CA3094749A1 (https=)
IL (1) IL277474B2 (https=)
WO (1) WO2019186369A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250533A1 (en) * 2020-06-09 2021-12-16 Novartis Ag Methods of treatment using omalizumab or ligelizumab
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
CA3220757A1 (en) * 2021-06-14 2022-12-22 Novartis Ag Pharmaceutical formulation containing an anti-ige antibody
EP4384553A1 (en) * 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524602A (ja) 2003-04-04 2007-08-30 ジェネンテック・インコーポレーテッド 高濃度抗体及びタンパク質製剤
JP2008507474A (ja) 2004-02-02 2008-03-13 タノックス インコーポレイテッド 新規のＩｇＥエピトープの同定

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
SI2000481T1 (sl) * 2003-02-01 2016-08-31 Tanox, Inc. Anti-humana protitelesa IgE z visoko afiniteto
US20130005708A1 (en) * 2011-06-29 2013-01-03 Lalwani Dinusha N Histamine antagonist treatment of inflammatory skin disorders
TW201343176A (zh) * 2012-04-16 2013-11-01 Novartis Ag 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
CN104547325A (zh) * 2015-01-21 2015-04-29 李健 一种治疗慢性特发性荨麻疹的药物组合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524602A (ja) 2003-04-04 2007-08-30 ジェネンテック・インコーポレーテッド 高濃度抗体及びタンパク質製剤
JP2008507474A (ja) 2004-02-02 2008-03-13 タノックス インコーポレイテッド 新規のＩｇＥエピトープの同定

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clinical Trial Protocol [CQGE031 C2202 / NCT03437278] "A multicenter, randomized, double-blind, placebo-controlled phase 2b dosefinding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous Urticaria (CSU)"，2018年01月18日，p.1-85，Retrieved from the Internet: <URL:https://clinicaltrials.gov/ProvidedDocs/78/NCT03437278/Prot_000.pdf>
History of Change for Study:NCT03437278, [online], ClinicalTrials.gov archive, NCT ID:NCT03437278，2018年02月12日，[Retrieved on 2023-04-04]，Retrieved from the internet:<URL: https://classic.clinicaltrials.gov/ct2/history/NCT03437278?V_1=View#StudyPageTop>

Also Published As

Publication number Publication date
JP2021523881A (ja) 2021-09-09
US20210115155A1 (en) 2021-04-22
KR20200135826A (ko) 2020-12-03
EP3773904A1 (en) 2021-02-17
US20250026858A1 (en) 2025-01-23
WO2019186369A1 (en) 2019-10-03
RU2020134794A (ru) 2022-04-26
IL277474B1 (en) 2025-12-01
IL277474B2 (en) 2026-04-01
IL277474A (en) 2020-11-30
CA3094749A1 (en) 2019-10-03
RU2020134794A3 (https=) 2022-04-26
AU2019244666A1 (en) 2020-10-08
CN112203724A (zh) 2021-01-08

Similar Documents

Publication Publication Date Title
EP3111954B1 (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies
JP2025106377A (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
US20250026858A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
US20230235069A1 (en) Treatment of atopic dermatitis
US20230009657A1 (en) Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
JP2022549218A (ja) 抗トリプターゼ抗体の投薬
US10676522B2 (en) Methods of selectively treating asthma using IL-17 antagonists
RU2783540C2 (ru) Способы лечения хронической спонтанной крапивницы с применением лигелизумаба
WO2018158741A1 (en) Psoriasis disease modification following long-term treatment with an il-17 antagonist
WO2025166118A1 (en) Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
CN118488851A (zh) 特应性皮炎的治疗
HK40035240B (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241113

R150 Certificate of patent or registration of utility model

Ref document number: 7589045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150